Central Venous Epicutaneo Cava Catheter Articles & Analysis: Older
7 articles found
Patients who need medical treatment often fear being exposed to harmful germs and unsanitary instruments. Just the thought of a healthcare provider using an unsterilized surgical device or needle is enough to make people feel queasy. As a result, patients find it reassuring to watch a clinician remove healthcare devices from sterile packaging before starting a procedure. Sterile packaging ...
The FDA's Center for Drug Evaluation and Research (CDER) regulatory approval of a total of 26 NME (New Molecular Entity) drugs in the first half of 2023. It is worth noting that the 26 drugs approved include 4 peptide drugs, accounting for 15% of the total. In the past 2022, the FDA has approved only three peptide drugs: Tirzepatide, Lutetium 177Lu Vipivotide Tetraxetan and Terlipressin, of which ...
For patients and parents recently affected by or managing short bowel syndrome, TPN is likely new to their vocabulary. While any clinical acronym may sound overwhelming, TPN is not such a complicated one to understand. ...
No parent wants to hear their child has a condition that might affect their education, family life, and overall well-being. Unfortunately, there’s currently no restorative treatment for short bowel syndrome (SBS). Monitoring nutrition is a lifelong necessity for anyone with this disorder. This means that no matter the cause of SBS, there are certain things you should know about nutrition ...
Objective: Patients with end stage renal failure who require haemodialysis suffer morbidity and mortality due to vascular access. Bioengineered human acellular vessels (HAVs) may provide a haemodialysis access option with fewer complications than other grafts. In a prospective phase II trial from 2012 to 2014 (NCT01744418), HAVs were implanted into 40 haemodialysis patients at three sites in ...
Keywords Vascular access · Hemodialysis · Healthcare costs · Health economics · Arteriovenous fistula · Arteriovenous graft Abstract Introduction: Hemodialysis (HD) in end-stage renal disease (ESRD) patients requires vascular access (VA) through an arteriovenous fistula (AVF), a prosthetic arteriovenous graft (AVG), or a central venous catheter. While AVF or ...
Background: Arteriovenous fistulae are the currently recommended gold standard vascular access modality for haemodialysis because of their prolonged patency, improved durability, and low risk of infection for those that mature. However, notable disadvantages are observed in terms of protracted maturation time, associated high rates of catheter use, and substantial abandonment rates. The aim of ...